1. Home
  2. ASGI vs LXRX Comparison

ASGI vs LXRX Comparison

Compare ASGI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASGI

abrdn Global Infrastructure Income Fund of Beneficial Interest

HOLD

Current Price

$23.76

Market Cap

753.6M

Sector

Finance

ML Signal

HOLD

LXRX

Lexicon Pharmaceuticals Inc.

HOLD

Current Price

$1.68

Market Cap

660.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASGI
LXRX
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.6M
660.9M
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
ASGI
LXRX
Price
$23.76
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.15
AVG Volume (30 Days)
134.4K
2.1M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.78
EPS
N/A
N/A
Revenue
N/A
$49,803,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
60.24
52 Week Low
$18.53
$0.51
52 Week High
$25.95
$1.95

Technical Indicators

Market Signals
Indicator
ASGI
LXRX
Relative Strength Index (RSI) 51.47 47.92
Support Level $21.81 $1.47
Resistance Level $24.59 $1.81
Average True Range (ATR) 0.42 0.10
MACD 0.00 -0.01
Stochastic Oscillator 42.46 31.25

Price Performance

Historical Comparison
ASGI
LXRX

About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest

abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.

About LXRX Lexicon Pharmaceuticals Inc.

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Share on Social Networks: